What principles should govern the use of managed entry agreements?

International Journal of Technology Assessment in Health Care

Volumn 27, Issue 1, 2011, Pages 77-83

  Klemp, Marianne ^a   Frønsdal, Katrine B ^a   Facey, Karen ^b  

^a NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

(MeSH) Insurance; Biomedical; Health; Reimbursement; Reimbursement mechanisms; Technology assessment; Treatment outcome

Indexed keywords

(MESH) INSURANCE; BIOMEDICAL; REIMBURSEMENT; REIMBURSEMENT MECHANISMS; TECHNOLOGY ASSESSMENT; TREATMENT OUTCOME;

HEALTH; HEALTH CARE; OPTIMIZATION; RATING; TECHNOLOGY TRANSFER;

INNOVATION;

ARTICLE; BUDGET; DECISION MAKING; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HEALTH SERVICE; MANAGED ENTRY AGREEMENT; MEDICAL TECHNOLOGY; PRODUCTIVITY; REIMBURSEMENT; WORKSHOP; EDUCATION; HEALTH CARE DELIVERY; HUMAN; ORGANIZATION AND MANAGEMENT; TIME;

BIOMEDICAL TECHNOLOGY; EDUCATION; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; TIME FACTORS;

EID: 79955701065     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462310001297     Document Type: Article

References (18)

1. Adams CP, Brantner VV. Spending on new drug development. Health Econ. 2010;19:130-141.
2. Australian Government, Department of Health and Age¬ing. Pharmaceutical benefits scheme. http://www.pbs.gov. au/html/industry/static/how- to-list-on-the-pbs/elements-of- the-listing-process/guidelines-for-deeds-of- agreement (accessed June 2010).
3. Bell KJ, Irwig L, March LM, et al. Should response rules be used to decide continued subsidy of very expensive drugs? A checklist for decision makers. Pharmacoepidemiol Drug Saf. 2010;1:99-105.
4. Briggs A, Ritchie K, Fenwick E, Chalkidou K, Littlejohns P. Access with evidence development in the UK: Past experience, current initiatives and future potential. Pharmacoeconomics. 2010;28:163-170.
5. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veen-straa DL. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96:179-190.
6. Daniels N, Sabin JE. Accountability for reasonableness: An update. BMJ. 2008;337:a1850.
7. Eichler HG, Bloechl-Daum B, Abadie E, et al. Relative efficacy of drugs: An emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov. 2010;9:277-291.
8. Frønsdal KB, Facey K, Klemp M, et al. Health technology as¬sessment to optimize health technology utilization: Using im¬plementation initiatives and monitoring processes. Int J Technol Assess Health Care. 2010;26:309-318.
9. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finas-teridein men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327:1185-1191.
10. High Level Pharmaceutical Forum 2005-2008. Final con¬clusions and recommendations of the High Level Pharma¬ceutical Forum. http://ec.europa.eu/pharmaforum/docs/final- conclusions-en.pdf (accessed March 2010).
11. Hutton J, Trueman P, Henshall C. Coverage with evidence de¬velopment: An examination of conceptual and policy issues. Int J Technol Assess Health Care. 2007;2:425-435.
12. MacLeod S, Mitton C. We know accurately only when we know little. Pharmacoeconomics. 2010;28:1-3.
13. McCabe C, Stafinski T, Edlin R, Menon D, for and on behalf of the Banff AED. Summit. Access with evidence development schemes: A framework for description and evaluation. Phar-macoeconomics. 2010;28:1-10.
14. Mohr PE, Tunis SR. Access with evidence development: The US experience. Pharmacoeconomics. 2010;28:153-162.
15. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: The pharmaceutical industry's grand chal¬lenge. Nat Rev Drug Discov. 2010;9:203-214.
16. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular de¬generation. N Engl J Med. 2006;355:1419-1431. (Pubitemid 44511557)
17. Sox HC, Greenfield S. Comparative effectiveness research: A report from the Institute of Medicine. Ann. Intern Med. 2009;151:203-205.
18. Stafinski T, McCabe CJ, Menon D. Funding the unfundable: Mechanisms for managing uncertainty in decisions on the in¬troduction of new and innovative technologies into healthcare systems. Pharmacoeconomics. 2010;28:1-29.